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Abstract
Background: Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to
medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS
patients on fampridine treatment for 12 months in Germany were analyzed.
Methods: A retrospective claims database analysis was conducted including MS patients who initiated fampridine
treatment (index date) between July 2011 and December 2013. Continuous insurance enrollment during 12 months
pre- and post-index date was required, as was at least 1 additional fampridine prescription in the fourth quarter
after the index date. Patient characteristics were evaluated and pre- vs post-index MS-related healthcare utilization
and costs were compared.
Results: A total of 562 patients were included in this study. The mean (standard deviation [SD]) age was 50.5 (9.8)
years and 63% were female. In the treatment period, almost every patient had at least 1 MS-related outpatient visit,
24% were hospitalized due to MS, and 79% utilized MS-specific physical therapy in addition to the fampridine
treatment. Total MS-related healthcare costs were significantly higher in the fampridine treatment period than in
the period prior to fampridine initiation (€17,392 vs €10,960, P < 0.001). While this difference was driven primarily by
prescription costs, MS-related inpatient costs were lower during fampridine treatment (€1,333 vs €1,565, P < 0.001).
Conclusions: Physical therapy is mainly used concomitant to fampridine treatment. While healthcare costs were
higher during fampridine treatment compared to the pre-treatment period, inpatient costs were lower. Further
research is necessary to better understand the fampridine influence.
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Background
Multiple sclerosis (MS) is a chronic and progressive
autoimmune disease of the central nervous system. MS
patients suffer from diverse symptoms, whereas gait dis-
turbance is one of the major problems that occurs fre-
quently [1–3]. An estimated 40 to 90% of patients with
MS experience walking impairment [1, 4, 5]. Fampridine
is the first and only available medical treatment for im-
proving walking ability in patients with MS and it has
been licensed since 07/2011 in Europe [6]. The fampri-
dine tablets (10 mg) are given twice a day, and if no
improvement is shown after 2 weeks, the treatment
should be stopped [6].
Due to its relative novelty, no information on
fampridine-treated patients under real-life conditions is
available in Germany. This information can contribute
to understanding the unmet needs of this patient group.
Furthermore, limited data assessing the resource impli-
cations of treating MS mobility symptoms are available.
This study aims at identifying the treatment, patient
characteristics, MS-related healthcare resource use, and
costs of patients staying on fampridine therapy for 1 year
after treatment initiation. Furthermore, a comparison of
the MS-specific healthcare resource use and costs during* Correspondence: jennifer.haas@xcenda.de
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fampridine treatment with the pre-treatment period
without fampridine was also conducted.
Methods
This retrospective claims data analysis was conducted
using data from the Health Risk Institute (HRI) research
database.
Database
The HRI research database comprises claims data from
75 of the 120 statutory health insurances in Germany.
The analysis sample includes the utilization and costs of
services for approximately 4 million covered lives
through 2014 on an anonymized, individual level. This
sample represents 4.8% of the population in Germany
and is already adjusted for age and gender for the Ger-
man population. Furthermore, the HRI research data-
base is considered to have good external validity to the
German population in terms of morbidity, mortality, and
drug use [7].
Patient selection
All adult patients initiating treatment with fampridine
between July 2011 and December 2013 in the database
were identified, and the first prescription fill of fampri-
dine (Anatomical Therapeutic Chemical code N07XX07)
in this period determined the index quarter. Patients
were included if they were continuously enrolled 4 quar-
ters before and 4 quarters after the index quarter. At
least 1 MS diagnosis (International Classification of Dis-
eases, 10th Revision, German Modification [ICD-10-
GM] G35.XX) in the inpatient sector (main or secondary
diagnosis) or in the outpatient sector (verified diagnosis)
during the index quarter or the preceding quarters was
required. Furthermore, at least 1 additional fampridine
prescription fill in the fourth quarter after the index
served as a proxy indicating continuous fampridine
treatment within the post-index period.
The identified patients were then stratified by DMT
use, age and by use of antispasmodics to identify differ-
ences related to specific patient characteristics.
The full study population was stratified according to
their disease-modifying therapy (DMT) use during the
study period, defined as “continuous DMT”, “discontinu-
ous DMT” and “no DMT”. This stratification was per-
formed to isolate the effect of fampridine from possible
effects of DMT treatment. The included DMTs were
intramuscular (IM) interferon (INF) beta-1a, subcutane-
ous (SC) INF beta-1a, INF beta-1b, glatiramer acetate,
natalizumab, teriflunomide, dimethyl fumarate, and fin-
golimod. Continuous DMT users were required to have
at least 1 prescription claim for a DMT in the fourth
quarter before the index quarter, 1 in the index quarter
itself, and 1 in the fourth quarter after the index quarter.
Switches between the DMTs were not permitted in this
subgroup. The discontinuous DMT cohort was defined
as having a prescription claim for at least 1 DMT in any
of the 9 quarters (4 quarters pre-index, index quarter,
and 4 quarters post-index) where DMT switches were
allowed. The subgroup of patients with no DMT had no
prescription claims for any DMT in any of the 9 study
quarters.
The second stratification divided the study population
by age, including the subgroups aged 18 to 49 years and
≥50 years of age.
For the third stratification, all fampridine patients were
subdivided into users and non-users of antispasmodic
treatment. Users were defined as having at least 1 pre-
scription of an antispasmodic treatment (baclofen, botu-
linum toxin, dantrolene, tizanidine, tolperisone,
tetrazepam, gabapentin, cannabinoids) anytime during
the 24-month observation period. Non-users had no evi-
dence of symptomatic treatment within the study
period.
Outcomes
Patient characteristics, including demographics, co-
medication use (including DMTs and other MS-related
medications using Anatomical therapeutic chemical clas-
sification system [ATC] codes), and comorbidities mea-
sured with the Charlson Comorbidity Index (CCI), and
the most frequent diagnoses (top 10) in the 4 quarters
before the index fampridine prescription were assessed.
The outcomes consisted of MS-related healthcare re-
source use for the inpatient, outpatient, and pharmaco-
therapy sectors. For the inpatient stays, MS-specific
hospital visits were those with the MS ICD-10-GM code
G35.XX as the primary diagnosis. Outpatient diagnoses
were coded by different physician specialties, including
but not limited to: general practitioners, neurologists,
emergency physicians, and internists. The diagnoses are
only coded on a quarterly basis and not directly linked
to an intervention in the German healthcare system;
therefore, an approximation of MS-related outpatient
visits was assessed by calculating the number of visits
with an MS ICD-10-GM diagnosis code in the same
quarter. The same method was applied for the physical
therapy visits. Furthermore, corticosteroid prescription
fills, MS-related sick leave days (with a MS ICD-10-GM
diagnosis code), and prescriptions for mobility-related
devices were also assessed (eg, wheelchair, cane, etc.).
The MS-related healthcare costs in Euros were calcu-
lated using the costs for the use of resources described
above. Pharmacotherapy costs included the corticoster-
oid prescriptions, DMTs, fampridine, and other MS-
related medications, including antidementia; antidepres-
sants; antiepileptic; urinary antispasmodics; selected
muscle relaxants such as baclofen, botulinum toxin,
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dantrolene, tizanidine, tolperisone, and tetrazepam; se-
lected medications to manage fatigue such as amanta-
dine and modafinil; selected drugs for sexual
dysfunction such as sildenafil, tadalafil, and tibolone;
selected drugs against tremor such as propranolol; as
well as benzodiazepine, and cannabinoids, according
to Deutsche Gesellschaft für Neurologie (German
Neurological Society) [8], Hoer et al. [9], and Bona-
fede et al. [10] The costs were then adjusted for infla-
tion for the year 2014 using the general rate of
inflation for Germany [11].
Baseline patient characteristics were assessed in the
pre-index period. Healthcare utilization and costs for the
1-year treatment period were analyzed using descriptive
statistics. Baseline characteristics, healthcare resource
use, and costs were also stratified by the subgroups pre-
viously noted. Mean change (pre – post) and SD were
computed for continuous healthcare resource use and
cost measures. One-sample t-tests or Wilcoxon signed-
rank tests were used for the evaluation of change mea-
sures (pre – post), depending on the distributional prop-
erties of the measure under evaluation. A P-value <0.05
denoted statistical significance and the statistical soft-
ware SAS version 9.2 (SAS Institute, Cary NC, USA)
was used for all analyses.
Results
Patient characteristics
Out of 1318 identified patients treated with fampridine,
43% (N = 562) met all study criteria. Most of the patients
were excluded because they did not have a fampridine
prescription fill in the 4th quarter after the index quarter.
The mean age was 50.5 years and 63% were female. The
most frequently prescribed medications in the pre-index
period were muscle relaxants with 40.4% (such as baclo-
fen with 26.2%) and antidepressants (31.9%) (see Table 1).
On average, fampridine was prescribed 11 times per pa-
tient in the 12-month post-index period (SD 3.4).
MS-related healthcare resource use and costs before and
during fampridine treatment
Regarding the MS-related resource utilization, a high
percentage of patients had at least 1 MS-related physical
therapy and 1 MS-related outpatient visit during fampri-
dine treatment. One-third of patients had a prescription
claim for corticosteroids, and the average number of
corticosteroid prescriptions was 0.78 (SD 1.38). Further-
more, 1 in 5 patients had at least 1 day of sick leave due
to MS, with a total of 12.6 (SD 45.5) MS-related sick
leave days on average.
Compared to the pre-index period, significant reduc-
tions were observed in inpatient stays and corticosteroid
use during the fampridine treatment period. The mean
number of sick leave days decreased by 2 days, although
the difference was not statistically significant (14.7 days
[SD 46.8] vs 12.6 days [SD 45.5] P = 0.195). The percent-
age of patients using physical therapy and with out-
patient visits increased significantly between the time
periods (see Fig. 1).
Data not shown for the pre- and post-index MS-
related resource use has been added as supplementary
material (Additional file 1).
The overall average number of MS-related outpatient
visits was 19 per year (SD 10.4) during the treatment
period, implying that 1.6 physician visits per month due
to MS were usual for the fampridine-treated patients.
The majority of patients had at least 1 MS-related visit
at their general practitioner (GP) (7.5 visits on average,
SD 7.4). Less than half of the patients visited a neurolo-
gist during the fampridine treatment period (4.1 visits
on average, SD 5.9).
MS-related healthcare costs before and during fampridine
treatment
After pharmacotherapy, the second highest costs were
observed for the inpatient sector. Devices for mobility
problems were the smallest cost component, with 0.05%
of the total MS-related healthcare costs during the ob-
servation period.
Compared with the pre-index period, MS-related in-
patient costs declined significantly during fampridine
treatment (€1,565.42 vs €1,333.42; P < 0.001), whereas
MS-related outpatient costs increased significantly dur-
ing the same period (€518.09 vs €565.47; P < 0.0001) (see
Table 2).
Stratified analyses
About one-quarter of the identified patients had con-
tinuous DMT treatment and most (46%) did not use any
DMT during the whole study period. Just under one-half
(48%) of patients were younger than 50 years of age and
more than half (53%) used antispasmodics at least once
(53%) (see Fig. 2).
DMT stratification
Overall, a greater proportion of patients (46%) had no
evidence of DMT treatment during the full observation
period, compared with discontinuous DMT use (29%),
and continuous use (26%). These subgroups differed in
age, comorbidities, MS-related inpatient stays and costs,
and MS-related sick leave.
Concerning the inpatient stays, those with discontinu-
ous DMT use had the highest proportion with MS-
related hospitalizations (30%) in contrast to the no DMT
(27%) and the continuous DMT (10%) subgroups. How-
ever, the decline in MS-related stays from the pre- to
post-index period was the highest and only significant in
the no DMT subgroup (35–27%, P = 0.007).
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In addition, the mean number of sick leave days and
corticosteroid prescriptions declined significantly during
the fampridine treatment period within the no DMT co-
hort (MS-related sick leave days: mean, 12.0–5.7 days, P
= 0.002; corticosteroid prescriptions: 0.9–0.7, P = 0.013).
The inpatient costs declined significantly from the
pre- to the post-index period in the no DMT subgroup
Table 1 Patient characteristics
Characteristic N = 562
Age in years, mean (SD) 50.5 (9.8)
Median 50.5
Minimum, maximum 23.7, 79.2









Female, n (%) 352
(62.6%)







MS ICD-10-GM codes at index quarter, n (%)a
G35.0: Initial manifestation of MS 92 (16.4%)
G35.1: Mainly relapsing/remitting MS 288
(51.2%)
G35.2: Primary progressive MS 121
(21.5%)
G35.3: Secondary progressive MS 175
(31.1%)
G35.9: MS, unspecified 450
(80.1%)
Exclusively unspecified diagnosis (G35.9) 85 (15.1%)
First prescribed DMT, n (%)c
IM INF beta-1a 50 (8.9%)
SC INF beta-1a 48 (8.5%)
SC INF beta-1b 59 (10.5%)




Dimethyl fumarate 3 (0.5%)
None 257
(45.7%)




Drugs for symptom relief, n (%)d
Antidementia 6 (1.1%)








Medications to manage fatigue 37 (6.6%)
Medications for tremor 2 (0.4%)
CCI, mean (SD)d 1.08 (1.39)
Median 0







Top 10 diagnoses using ICD-10-GM codes (n, %)d
H52.2: Astigmatism 158
(28.1%)




F32.9: Depressive episode unspecified 122
(21.7%)








N31.9: Neuromuscular dysfunction of bladder unspecified 101
(18.0%)




N39.4: Other specified urinary incontinence 99 (17.6%)
G82.1: Spastic paraplegia 98 (17.4%)
Abbreviations: CCI Charlson Comorbidity Index, DMT disease-modifying therapy,
ICD-10-GM International Classification of Diseases, 10th Revision, German Modi-
fication, IM intramuscular, INF interferon, MS multiple sclerosis, SC subcutane-
ous, SD standard deviation
aMore than 1 diagnosis was possible during the index quarter; bcalculated only
for females
cmeasured in the whole period of 9 quarters (4 quarters pre-index, 1 quarter
index, 4 quarters post-index)
dmeasured in the 4 quarters before the index fampridine prescription
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(€2,004 vs €1,600, P < 0.001), whereas no significant dif-
ferences could be observed within the other subgroups
(€458 vs €457, P = 0.872 continuous DMT subgroup;
€1,856 vs €1,691, P = 0.174 discontinuous DMT sub-
group). Partly due to the lack of DMT costs, the no
DMT subgroup had the lowest MS-related healthcare
costs (€9,197), with €26,984 in the continuous DMT
subgroup and €21,893 in the discontinuous DMT
subgroup.
Stratification by age
Almost half of the patients were younger than 50 years
(48%), and older patients had a higher CCI than younger
patients (1.81 vs 1.06). Over half (57%) of the older and
one-third (34%) of the younger age subgroups did not
use DMTs. During fampridine treatment, 27% of the
younger subgroup and 21% of the older subgroup had
MS-related inpatient stays. These rates of MS-related
hospitalization were significantly lower than in the pre-
index period, with 33% in the younger age subgroup (P
< 0.05) and 26% in the older age subgroup (P < 0.05)
hospitalized.
Total MS-related healthcare costs in the treatment
period for those aged ≥50 years were €14,920, and
€20,804 for those aged 18 to 49 years. The second high-
est cost component next to pharmacotherapy was the
inpatient sector among the younger aged subgroup and
physical therapy in the older aged subgroup.
Stratification by antispasmodic treatment
Fifty-three percent (n = 297) of the fampridine patients
had at least 1 prescription claim for antispasmodics dur-
ing the study period. Twenty-seven percent of these had
MS-related inpatient stays. Among the antispasmodic
non-users, 20% were hospitalized due to MS in the post-
index period. In the pre-index period, the MS-related
hospitalizations were significantly higher, with 33% (P <
0.05) and 26% (P < 0.05) compared to the post-index
period for the users and non-users, respectively. The
MS-related total costs were €18,100 in the antispas-
modic non-user subgroup and €16,760 in the antispas-
modic user subgroup (see Fig. 3).
Discussion
This study shows the differences in MS-related health-
care resource use and costs of patients in Germany initi-
ating and continuing treatment with fampridine for at
least 12 months compared to the 12 months prior to
treatment initiation.
Patients starting fampridine treatment were, on
average, 50 years old, which demonstrates that the
disease had already progressed, as the average age for
disease onset is 30 [12]. The mean age at the start of
fampridine therapy, however, is slightly lower in
Germany than in the United States (US), where the
mean age is 55 years [13].
Before commencing fampridine treatment, many pa-
tients used medications such as muscle relaxants and
antidepressants, which is similar to other findings [13].
The percentage of non-DMT users was slightly higher
with 46% in this German population compared to 38%
of MS patients in the US, as noted by M Jara, MF Sido-
var and HR Henney [13] in 2014. Almost every patient
had at least 1 outpatient visit, 24% were hospitalized due
to MS in the treatment period, and 81% utilized physical
therapy in addition to fampridine treatment. This study
reveals that the combination of fampridine treatment
and physical therapy is common in Germany, supporting
the fact that fampridine is used complementary to rather
than in place of physical therapy [14, 15] whereas
Fig. 1 MS-related resource utilization in the 12 months before and during fampridine treatment
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physical therapy was deemed the appropriate compara-
tor in the fampridine German Arzneimittelmarkt-
Neuordnungsgesetz AMNOG) (ie, evaluation of new
pharmaceuticals in Germany) value dossier. However, as
the requested comparison did not include sufficient data,
no additional benefit was stated [14]. The significant re-
ductions in corticosteroid use and inpatient stays after
initiating fampridine might be due to improvement of
mobility problems. Improvement could also be due to
the increase in physical therapy. Furthermore, the in-
creasing use of physical therapy might also suggest that
patients became more active to deal with mobility issues
after experiencing the benefit from fampridine. It is also
possible that individuals motivated to initiate and adhere
to fampridine treatment might also be subsequently mo-
tivated to attend physical therapy sessions. In addition to
physical therapy, other outpatient care played an import-
ant role in treating MS (approximately 19 visits per year
per patient), as GPs were contacted at least twice and
neurologists at least once per quarter. M Jara, MF Sido-
var and HR Henney [13] reported that 79.1% of the first
fampridine prescriptions were prescribed by neurologists
in the US, which is higher than the estimated 45% of MS
patients visiting a neurologist for their MS in our study.
The total MS-related healthcare costs were signifi-
cantly higher in the fampridine treatment period com-
pared to the period before fampridine treatment, mainly
due to the increased pharmacotherapy costs.
Table 2 MS-related healthcare costs before and during fampridine treatment
Pre-index period (before fampridine
treatment)
Observation period (during fampridine
treatment)
P-value
N = 562 N = 562
Inpatient, mean (SD) €1,565.42 (€3,335.18) €1,333.42 (€3,882.73) 0.0005
Median €0 €0
Minimum, maximum €0, €30,568.04 €0, €62,415.54
Physical therapy, mean (SD) €810.89 (€887.80) €963.92 (€925.50) <0.0001
Median €613.28 €825.40
Minimum, maximum €0, €8,015.80 €0, €6,945.80
Outpatient, mean (SD) €518.09 (€341.78) €565.47 (€338.85) <0.0001
Median €459.33 €508.52
Minimum, maximum €0, €2,794.88 €0, €2,851.23
Pharmacotherapy
DMTs, mean (SD) €7,684.42 (€8,908.24) €8,604.78 (€9,948.43) <0.0001
Median €0 €0
Minimum, maximum €0, €29,157.08 €0, €33,639.54
Corticosteroids, mean (SD) €108.24 (€194.47) €88.88 (€181.15) 0.0054
Median €0 €0
Minimum, maximum €0, €989.38 €0, €1,041.33
Fampridine, mean (SD) €0 (€0) €5,519.32 (€1,565.83) <0.0001
Median €0 €5,908.53
Minimum, maximum €0, €0 €225.11, €10,033.99
Other MS-related prescriptions, mean
(SD)
€267.10 (€525.92) €306.90 (€642.63) 0.1229
Median €52.16 €55.53
Minimum, maximum €0, €4,782.96 €0, €7,358.06
Devices for mobility problems, mean (SD) €6.09 (€26.95) €9.17 (€58.20) 0.7468
Median €0 €0
Minimum, maximum €0, €344.01 €0, €1,146.39
Total MS-related healthcare, mean (SD) €10,960.26 (€9,030.32) €17,391.86 (€10,325.65) <0.0001
Median €9,376.59 €14,447.76
Minimum, maximum €0, €44,126.80 €1,107.41, €67,001.71
Bolded text indicates the main message – the mean values and the categories
Abbreviations: DMT disease-modifying therapy, MS multiple sclerosis, SD standard deviation
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Pharmacotherapy accounted for 82% of post-index
MS-related costs, followed by the inpatient sector,
with 8%. A high percentage of prescription costs rela-
tive to overall MS-related costs (65%) was also found
by JD Prescott, S Factor, M Pill and GW Levi [16] in
2004. However, in contrast to the increasing pharma-
cotherapy costs, the MS-related inpatient costs de-
clined during fampridine treatment compared to the
pre-treatment period (€1,333 vs €1,565, P < 0.001).
This means that while the main cost driver (pharma-
cotherapy) increased, the second highest cost compo-
nent (inpatient costs) declined simultaneously.
The different patient subgroup analyses revealed find-
ings that were consistent with the overall analysis. Pre-
scription costs were the highest in all subgroups, followed
by inpatient costs, except within the continuous DMT and
≥50-year-old subgroups, where physical therapy costs
were higher than the inpatient costs. However, slight dif-
ferences were observed, for example in the 3 subgroups
measuring DMT treatment concerning characteristics
such as age, comorbidity burden, and MS-related in-
patient stays. The no DMT subgroup mostly had signifi-
cant changes from pre- to post-fampridine initiation,
including MS-related hospitalizations, corticosteroid use,
Fig. 2 Subgroups
Fig. 3 MS-related healthcare costs by subgroup during fampridine treatment
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and MS-related sick leave days. It was assumed that these
patients were not relapsing-remitting MS patients; there-
fore, they had limited options for DMT treatment and
may benefit the most from fampridine. Another explan-
ation might be that without DMT treatment these patients
were more willing to adhere to fampridine treatment and
subsequently also physical therapy.
Several limitations of this study should be mentioned.
First, there were no comparisons to fampridine disconti-
nuers or non-users, and further research is warranted in
these areas as the results cannot be generalized to those pa-
tient groups. Second, no information on clinical outcomes,
such as Expanded Disability Status Scale scores, is available
in claims data, so the severity of the disability could not be
evaluated. Third, no adjustments, such as for the use of
physical therapy, outpatient visits, or disease progression,
were made and therefore the impact of these aspects on the
outcomes could not be estimated. Fourth, claims data are
not collected for research but instead for accounting pur-
poses and therefore include only sectors that are reim-
bursed by the statutory health insurance. Therefore,
indirect costs such as societal costs of MS-attributable in-
formal care could not be assessed. Additionally, compliance
with medication regimens could only be approximated
based on prescription fills, as the actual intake is not ob-
servable in this data source. Last, the number of outpatient
visits could only be approximated and may be underesti-
mated, as flat charges for outpatient visits on a quarterly
basis exist in Germany.
Conclusion
This study provides insights into the treatment of MS pa-
tients in Germany beginning treatment with fampridine and
continuing treatment for at least 12 months. These patients
visit the GP and neurologist regularly, and physical therapy
is used in combination with fampridine treatment in almost
every case. Besides the pharmacotherapy costs, the inpatient
costs were the second most important cost driver in all but
2 patient subgroups. Inpatient stays, as well as the costs, de-
clined during fampridine treatment compared to the pre-
treatment period. The overall costs, however, increased due
to the pharmaceutical costs. This cost increase might be jus-
tified due to improved patient outcomes beyond the reduced
healthcare utilization; however, patient reported outcomes
are not available within the Statutory Health Insurance. To
better understand fampridine influence in the real world,
further research is necessary.
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index period in a tabular format. (DOCX 17 kb)
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This study is a retrospective database analysis based on fully anonymized
claims data, and claims data are recorded for accounting purposes and not
for clinical research. No electronic medical records or other clinical
parameters were used. As a result, no ethical approval or consent from an
ethics committee or review board was required for this study.
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